Molecular and Cellular PharmacologyCurcumin induces down-regulation of EZH2 expression through the MAPK pathway in MDA-MB-435 human breast cancer cells
Introduction
Curcumin, a polyphenol isolated from the plant turmeric (Curcuma longa), has been found to inhibit cell proliferation in a variety of human cancer cell lines in vitro and has been used both to prevent and to treat various cancers in vivo (Kunnumakkara et al., 2008, Lopez-Lazaro, 2008). In breast cancer, it has been reported that curcumin was able to inhibit the expression of HER2, cyclin E, cyclin D1 and others (Hong et al., 1999, Mukhopadhyay et al., 2002, Aggarwal et al., 2007, Kim et al., 2008, Liu et al., 2009). These data provided evidence that the anticancer properties of curcumin in breast cancer might be attributable to the modulation of various molecular targets.
Recently, Margarita and colleagues reported that curcumin could down-regulate the protein expression of MEL18, a member of the polycomb group (PcG), in Hodgkin's lymphoma HD-MY-Z cells (Sanchez-Beato et al., 2004), suggesting that curcumin might be involved in the regulation of PcG proteins and related signaling pathways. It is known that the enhancer of zeste homolog 2 (EZH2) is a critical component of PcG proteins, and that EZH2 plays an important role in cell proliferation and cell cycle regulation (Tonini et al., 2008). Overexpression of EZH2 protein has been reported to be linked to invasive growth, aggressive clinical behavior and poor prognoses of breast cancers, and it has been suggested as a new molecular target for breast cancer treatment (Kleer et al., 2003, Raaphorst et al., 2003, Collett et al., 2006).
The aims of this study were therefore (a) to determine whether curcumin could inhibit the proliferation of breast cancer cells by regulating the expression and/or activity of EZH2; and if so, (b) to investigate its potential mechanism.
Section snippets
Materials
Curcumin (Sigma, St. Louis, MO) was dissolved in dimethyl sulfoxide (DMSO) at a concentration of 10 mM and stored in a dark-colored bottle at − 20 °C as a stock solution. The stock was diluted to the required concentration with serum-free medium immediately before use. The final DMSO concentration did not exceed 0.1% DMSO throughout the study. Antibodies against ERK1/2, phospho-ERK1/2 (Thr202/Tyr204), JNK1/2, phospho-JNK1/2(Thr183/Tyr185), p38, phospho-p38 (Thr180/Tyr182) and β-actin were obtained
Curcumin inhibits the proliferation of human breast cancer cell line MDA-MB-435.
MDA-MB-435 cells were exposed to various concentrations of curcumin for 12, 24 or 48 h, and their cellular proliferation was monitored. The results demonstrated that curcumin inhibited the proliferation of MDA-MB-435 cells. The anti-proliferative effects of curcumin were both dose- and time-dependent (Fig. 1A). A marked inhibition in cellular proliferation was observed in cells treated for 48 h with 50 μM curcumin compared with untreated control cells. Flow cytometric analysis was used to detect
Discussion
Breast cancer is one the most common human cancers and the second leading cause of cancer deaths in women in the United States (Jemal et al., 2008). It is therefore highly desirable that an effective chemotherapy agent against this form of cancer is developed as soon as possible. Curcumin, a natural polyphenol product isolated from the C. longa, has emerged in recent years as a promising anticancer therapeutic agent (Pari et al., 2008), and its anti-tumor properties have been reliably
Acknowledgments
This work was supported by grants from the Major State Basic Research Program of China (2006CB910104) and the 863 Project of China (2007AA021901).
References (27)
- et al.
Curcumin induces the degradation of cyclin E expression through ubiquitin-dependent pathway and up-regulates cyclin-dependent kinase inhibitors p21 and p27 in multiple human tumor cell lines
Biochem. Pharmacol.
(2007) - et al.
Curcumin, a novel p300/CREB-binding protein-specific inhibitor of acetyltransferase, represses the acetylation of histone/nonhistone proteins and histone acetyltransferase-dependent chromatin transcription
J. Biol. Chem.
(2004) - et al.
Curcumin inhibits proliferation, invasion, angiogenesis and metastasis of different cancers through interaction with multiple cell signaling proteins
Cancer Lett.
(2008) - et al.
Curcumin inhibits cell proliferation of MDA-MB-231 and BT-483 breast cancer cells mediated by down-regulation of NFkappaB, cyclinD and MMP-1 transcription
Phytomedicine
(2009) - et al.
Epi-drugs to fight cancer: from chemistry to cancer treatment, the road ahead
Int. J. Biochem. Cell Biol.
(2009) - et al.
Poorly differentiated breast carcinoma is associated with increased expression of the human polycomb group EZH2 gene
Neoplasia
(2003) - et al.
Cancer treatment of the future: inhibitors of histone methyltransferases
Int. J. Biochem. Cell Biol.
(2009) - et al.
Akt-mediated phosphorylation of EZH2 suppresses methylation of lysine 27 in histone H3
Science
(2005) - et al.
Lentivirus-mediated RNA interference targeting enhancer of zeste homolog 2 inhibits hepatocellular carcinoma growth through down-regulation of stathmin
Hepatology
(2007) - et al.
Curcumin induces c-jun N-terminal kinase-dependent apoptosis in HCT116 human colon cancer cells
Carcinogenesis
(2004)
Expression of enhancer of zeste homologue 2 is significantly associated with increased tumor cell proliferation and is a marker of aggressive breast cancer
Clin. Cancer Res.
Curcumin inhibits tyrosine kinase activity of p185neu and also depletes p185neu
Clin. Cancer Res.
Cancer statistics
CA Cancer J. Clin.
Cited by (0)
- 1
These authors contributed equally to this article.